Duration of antibiotic therapy in the intensive care unit.
暂无分享,去创建一个
P. Póvoa | I. Martín-Loeches | Gabor Zilahi | Mary Aisling McMahon | Pedro Povoa | Ignacio Martin-Loeches | G. Zilahi
[1] M. Kollef,et al. Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. , 2013, Chest.
[2] J. Jensen,et al. Procalcitonin increase in early identification of critically ill patients at high risk of mortality* , 2006, Critical care medicine.
[3] S. Jaber,et al. Procalcitonin biomarker kinetics fails to predict treatment response in perioperative abdominal infection with septic shock , 2013, Critical Care.
[4] M. Bonten,et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. , 2001, American journal of respiratory and critical care medicine.
[5] V. Nobre,et al. Procalcitonin Versus C-Reactive Protein for Guiding Antibiotic Therapy in Sepsis: A Randomized Trial* , 2013, Critical care medicine.
[6] J. Rello,et al. Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection? , 1998, American journal of respiratory and critical care medicine.
[7] V L Yu,et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. , 2000, American journal of respiratory and critical care medicine.
[8] A. Torres,et al. A week seems to be weak: tailoring duration of antibiotic treatment in Gram-negative ventilator-associated pneumonia , 2013, Critical Care.
[9] Peggy Cruse,et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] G. Webb,et al. Modeling antibiotic resistance in hospitals: the impact of minimizing treatment duration. , 2007, Journal of theoretical biology.
[11] M. Kollef,et al. Antimicrobial stewardship in the intensive care unit: advances and obstacles. , 2009, American journal of respiratory and critical care medicine.
[12] Marin H Kollef,et al. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. , 2004, Chest.
[13] Michel Wolff,et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.
[14] C. Clec’h,et al. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock , 2006, Critical care medicine.
[15] F. Tubach,et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial , 2010, The Lancet.
[16] Antonio Artigas,et al. What’s new in multidrug-resistant pathogens in the ICU? , 2016, Annals of Intensive Care.
[17] T. Similowski,et al. Invasive and Noninvasive Strategies for Management of Suspected Ventilator-Associated Pneumonia , 2000, Annals of Internal Medicine.
[18] E. Díaz,et al. Risks for multidrug-resistant pathogens in the ICU , 2014, Current opinion in critical care.
[19] J. Kline,et al. Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol* , 2011, Critical care medicine.
[20] W. Peetermans,et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study , 2009, Intensive Care Medicine.
[21] A. Torres,et al. Predicting treatment failure in patients with community acquired pneumonia: a case-control study , 2014, Respiratory Research.
[22] D. Baram,et al. Stable patients receiving prolonged mechanical ventilation have a high alveolar burden of bacteria. , 2005, Chest.
[23] R. Fowler,et al. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis , 2011, Critical care.
[24] A. Torres,et al. Impact of Candida spp. isolation in the respiratory tract in patients with intensive care unit-acquired pneumonia. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[25] M. Kollef,et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia , 2012, Critical Care.
[26] J. Carratalá,et al. Early and Late Treatment Failure in Community-Acquired Pneumonia , 2009, Seminars in respiratory and critical care medicine.
[27] Anthony S McLean,et al. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. , 2007, The Lancet. Infectious diseases.
[28] Richard Pugh,et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. , 2015, The Cochrane database of systematic reviews.
[29] Michel Wolff,et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. , 2017, The Cochrane database of systematic reviews.
[30] Hajo A. Bruining,et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. , 1995 .
[31] M. Niederman,et al. Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome* , 2003, Critical care medicine.